Breaking News

iBio, Caliber Select Cancer Target

By Kristin Brooks | January 15, 2014

To advance product on iBioLaunch platform

iBio, Inc. and Caliber Biotherapeutics have selected a fusion protein cancer treatment target to advance on the iBioLaunch platform under the companies’ licensing and collaboration agreement from February 2013. iBio will receive license and development milestones for product targets, as well as royalties on sales. Caliber is responsible for funding clinical development and commercialization. Additional financial terms were not disclosed.
 
"In addition to its other attributes, iBio technology produces antibodies efficiently," said Robert Erwin, iBio's president. "We are confident our technology will prove superior to traditional animal cell methods for efficient delivery of this promising new class of fusion-protein biotherapeutics, and we look forward to working with Caliber to rapidly move this molecule into clinical trials."
 
"This further collaboration with iBio gives us even more resources to rapidly optimize our production system," said Dr. Barry Holtz, Caliber Biotherapeutics' chief science and technology officer. "At Caliber we have an advantage in mAb development and large scale production. We do not have to develop a new cell line for each mAb construct. In addition, our bioreactors are individual plants so we do not have to scale-up to larger reactor components. We just grow 2.2 million individual bioreactors if necessary. This allows very rapid process and clinical development and shortens the time to large scale production and ultimately time to market."

blog comments powered by Disqus
  • Cold Chain Packaging Trends

    Cold Chain Packaging Trends

    Kristin Brooks, Contract Pharma||February 4, 2016
    Susan Li of UPS discusses supply chain trends, challenges, and packaging innovations

  • Packaging Equipment Trends Preview

    Packaging Equipment Trends Preview

    Kristin Brooks, Contract Pharma||January 26, 2016
    Christian Treitel of Bosch Packaging Technology discusses trends and capabilities

  • Filings Update

    Filings Update

    December 1, 2015
    Roche, Pfizer, Janssen, BMS and more

  • CMC Biologics: Growing Through Innovation

    Tim Wright, Editor||January 28, 2016
    The new chief exec talks about industry trends and growth plans.

  • Cold-Chain Logistics & The Central Lab

    Kristin Brooks, Associate Editor||January 28, 2016
    Eric Hayashi of LabConnect discusses safety measures to ensure sample integrity

  • A Look at DCAT Week ‘16

    Tim Wright, Editor||January 28, 2016
    On the pulse of the pharmaceutical manufacturing value chain, DCAT Week ‘16 will deliver top-flight education programs and networking events.